Iron Citrate Purity via Low-Temperature Precipitation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing iron(III) citrate often result in the inclusion of beta-iron hydroxide oxide, which is insoluble and reduces the purity of the compound, limiting its effectiveness in medical applications such as treating hyperphosphatemia.
Innovation Solution
A method involving the controlled reaction of ferric chloride with sodium hydroxide at low temperature to form an iron-containing precipitate, followed by treatment with citric acid to generate an aqueous solution of iron(III) citrate, and subsequent precipitation using an organic solvent to produce high-purity iron(III) citrate substantially free of beta-iron hydroxide oxide.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If ferric chloride is brought into contact with sodium hydroxide using conventional methods, then iron(III) citrate is produced, but beta-iron hydroxide oxide is formed as an impurity reducing purity
Solution Approach 1:
The patent applies parameter changes by controlling the reaction temperature (maintaining low temperature during precipitation), pH value (careful adjustment to appropriate range), and addition rate (controlled addition of sodium hydroxide) to prevent beta-iron hydroxide oxide formation while ensuring complete reaction, thereby achieving high purity iron(III) citrate
Solution Approach 2:
The patent employs preliminary action by pre-adjusting the pH value before adding sodium hydroxide, and pre-controlling the temperature conditions, to create optimal reaction conditions that prevent impurity formation from the outset rather than requiring subsequent purification steps
2Quantity of substance
If conventional production methods are used, then iron(III) citrate is obtained, but solubility is reduced due to beta-iron hydroxide oxide content
Solution Approach 1:
The patent uses parameter changes by optimizing reaction temperature, pH control, and addition rates to produce iron(III) citrate with high purity and improved solubility characteristics, eliminating the trade-off between purity and solubility
3Productivity
If the reaction is conducted without precise control, then production speed is faster, but purity of iron(III) citrate decreases
Solution Approach 1:
The patent applies parameter changes by establishing optimized reaction conditions including temperature control, pH adjustment rates, and addition speeds that enable both high production efficiency and high purity product simultaneously
Solution Approach 2:
The patent implements continuous controlled addition of reagents under optimized conditions, maintaining steady reaction progress without interruption or excessive speed, thereby achieving both high productivity and high purity through continuous optimized action
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high-purity iron(III) citrate with improved solubility and effectiveness as a phosphate binder, effectively reducing serum phosphorus levels and treating hyperphosphatemia.
Implementation Method 1
a step of forming an iron-containing precipitate by bringing ferric chloride into contact with sodium hydroxide for a short period of time at low temperature in an aqueous medium
Implementation Method 2
a step of generating an aqueous solution of iron(III) citrate by bringing citric acid into contact with the iron-containing precipitate in an aqueous medium and generating an aqueous solution of iron(III) citrate via heating
Implementation Method 3
a step of precipitating iron(III) citrate by bringing the aqueous solution of iron(III) citrate into contact with an organic solvent
Data Source
AI summary
This invention provides a method for producing high-purity iron(III) citrate substantially free of beta-iron hydroxide oxide, high-purity iron(III) citrate substantially free of beta-iron hydroxide oxide, and medical uses thereof.